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Abstract
Background: A significant reduction in parasite clearance rates following artesunate treatment of falciparum
malaria, and increased failure rates following artemisinin combination treatments (ACT), signaled emergent
artemisinin resistance in Western Cambodia. Accurate measurement of parasite clearance is therefore essential to
assess the spread of artemisinin resistance in Plasmodium falciparum. The slope of the log-parasitaemia versus time
relationship is considered to be the most robust measure of anti-malarial effect. However, an initial lag phase of
numerical instability often precedes a steady exponential decline in the parasite count after the start of anti-
malarial treatment. This lag complicates the clearance estimation, introduces observer subjectivity, and may
influence the accuracy and consistency of reported results.
Methods: To address this problem, a new approach to modelling clearance of malaria parasites from parasitaemia-
time profiles has been explored and validated. The methodology detects when a lag phase is present, selects the
most appropriate model (linear, quadratic or cubic) to fit log-transformed parasite data, and calculates estimates of
parasite clearance adjusted for this lag phase. Departing from previous approaches, parasite counts below the level
of detection are accounted for and not excluded from the calculation.
Results: Data from large clinical studies with frequent parasite counts were examined. The effect of a lag phase on
parasite clearance rate estimates is discussed, using individual patient data examples. As part of the World Wide
Antimalarial Resistance Network’s (WWARN) efforts to make innovative approaches available to the malaria
community, an automated informatics tool: the parasite clearance estimator has been developed.
Conclusions: The parasite clearance estimator provides a consistent, reliable and accurate method to estimate the
lag phase and malaria parasite clearance rate. It could be used to detect early signs of emerging resistance to
artemisinin derivatives and other compounds which affect ring-stage clearance.
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Background
Anti-malarial drug resistance is a major cause of preven-
table mortality [1] and poses the main threat to current
global efforts to control and eliminate malaria [2].
Replacement of failing mono-therapy with highly effec-
tive artemisinin combination therapy (ACT) and
increased delivery of effective vector control measures
have reversed the increasing malaria mortality trend
observed in the 1980s and 1990s. ACT has now become
the recommended first line treatment for falciparum
malaria in nearly all malaria affected countries [3].
The recent emergence of artemisinin resistance in
Plasmodium falciparum malaria in Western Cambodia
represents a considerable threat to global health [4-6]. A
significant reduction in the rates of parasite clearance
following treatment with artesunate and increased fail-
ure rates following artemisinin combination treatments
(ACT) provided definitive evidence of resistance in that
region [5,7,8]. There is increasing concern that
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molecular marker of artemisinin resistance has yet been
identified, and in vitro assessments have given contra-
dictory results [5-7]. The clinical phenotype of slow
parasite clearance remains to date the only way to
define artemisinin resistance reliably [10].
T h eu n i q u ea b i l i t yo ft h ea r t e m i s i n i nd e r i v a t i v e st o
accelerate the clearance of ring stage infected erythro-
cytes is their pharmaco-dynamic hallmark [11,12]. Accu-
rate measurement of the rate of parasite clearance is
necessary to assess artemisinin susceptibility in vivo.
Most in vivo assessments measure parasitaemia either
daily, or only on days D0, D2 and D3, as recommended
in the current World Health Organization (WHO)
guidelines [6]. In most studies, the exact timing of the
parasite count is not recorded and could vary by several
hours depending on the timing of the visit to the clinic
at inclusion and during follow-up visits. The proportion
of patients with persistent parasitaemia at D3 after ACT
provides a useful indicator which can be used as a sim-
ple and readily obtained measure to exclude resistance,
but not to define resistance [13]. It is too inaccurate for
precise assessment as it is dependent on pre-treatment
parasite density, precise timing of the sample, and it
requires large sample sizes for precise estimates. In pre-
vious studies, with more frequent sampling, several dif-
ferent methods of analysing and measuring parasite
clearance have been employed but systematic analytical
approaches to measurement have not been taken.
The slope of the log-parasitaemia versus time relation-
ship is considered to be the most robust measure of
anti-malarial effect, but there are several potential
sources of error if a straight line is fitted to all log-
transformed parasite measurements, irrespective of the
shape of the relationship with time [14]. Changes in
parasitaemia, particularly during the first few hours after
anti-malarial drug administration, are affected by the
age distribution of the parasite population [15,16]. If the
majority of parasites in the peripheral blood film are
very young then it is likely that schizogony is still taking
place at the time of drug administration. Newly parasi-
tized erythrocytes will appear in the circulation shortly
afterwards. This may be reflected by a stable density or
even an increase in peripheral parasitaemia, despite
effective treatment. In these cases, the fitted line to the
log-parasitaemia versus time data will underestimate the
parasite counts at the initial time period and as a result
the slope of this line will underestimate the parasite
clearance. It is more appropriate to fit either a quadratic
m o d e li nt h ec a s ew h e r eal a gp h a s ei sf o l l o w e db ya
rapid decline in parasite number or a cubic model in
the case where a rapid decrease in parasitaemia is fol-
lowed by a flattening off of the parasitaemia-time
profile. Figure 1 shows typical linear, quadratic and
cubic-shaped log (parasitaemia)-time profiles (polyno-
mial fits are shown in the pink line).
In an attempt to standardize parasite clearance assess-
ments from parasitaemia-time profiles in P. falciparum
malaria, and facilitate epidemiological investigations of
artemisinin resistance a method of identifying the initial lag
phase and calculating a slope of log-parasitaemia changes
over time after this lag phase has been developed and
implemented into the parasite clearance estimator (PCE).
The algorithm chooses between three models (log-linear,
log-quadratic and log-cubic) and also provides automation
of the “cleaning” of parasite count data before model fitting.
The PCE may be used for any anti-malarial drug assess-
ment, although it has been tested in data from patients trea-
ted with artemisinin derivatives and various ACT.
In this paper, the details of a simple calculator (PCE)
that provides measures of parasite clearance from serial
parasite count data are presented including the back-
ground, terminology, method of use, and examples of its
application to real data.
Methods
Parasite clearance following any effective anti-malarial
treatment is a first order process, resulting in killing of
a fixed fraction of the parasite population in each asex-
ual cycle, and can be considered as the reciprocal of
parasite multiplication [11,17]. The predominant rela-
tionship between log-transformed parasite density and
time is generally linear [14,18,19]. Key terminology in
relation to parasite clearance estimation is presented
below.
Detection limit - for low parasite densities the thick
blood smear is used and the number of parasites (asex-
ual forms only i.e. trophozoites) are counted against the
number of white blood cells (usually 200 or 500). The
detection limit obviouslyd e p e n d so nt h en u m b e ro f
white blood cells counted. To estimate parasitaemia per
microlitre the following formula is used:
If ω is the number of white cells counted then
Parasitaemia per microlitre = number of parasites per slide × white blood cell count / ω
Ideally the white blood cell (wbc) count is measured
by an automated cell counter or manually. If this is not
available then the counts are assumed to be 8,000/uL.
When the white blood cell count is assumed 8,000 for all
patients, then the detection limit will be 40/uL for count-
ing per 200 wbc and 16/uL for counting per 500 wbc.
Negative parasite slide - when no parasites are seen
while the full number of white cells have been counted
then the parasite count is recorded as zero. Of course this
means only that the count is below the limit of detection,
although it is often reported or modeled as 0/uL.
Outliers - parasite counts which are not biologically
possible or are highly unlikely based on other parasite
Flegg et al. Malaria Journal 2011, 10:339
http://www.malariajournal.com/content/10/1/339
Page 2 of 13measurements in the same individual. These often result
from transcription errors.
Lag phase - initial part of the parasite clearance pro-
file which has a much flatter slope that the remaining
part of the profile. It is important to note that a lag
phase is not observed in all profiles.
Tail - terminal part of the parasite clearance profile
when parasitaemia remains close to the detection limit
(i.e. a few parasites per slide) and does not decrease
over a number of measurement time-points. Tails are
not observed in all profiles.
Clearance rate constant - the main part of parasitae-
mia clearance follows a first order process and therefore
the fraction by which parasite count falls per unit time
is constant. If parasitaemia at time t is given by Pt =
P0exp(-K×t), where P0 is the initial parasitaemia, then
the fractional reduction in a unit time is equal to (Pt=
1-P0)/P0 =1 - e
-K. The parameter K is the clearance rate
constant and is equal to the minus slope of the loge
parasitaemia-time linear relationship (that is, K > 0) as
loge(Pt) = loge(P0) - K×time. The clearance rate constant
is calculated after the tail and lag phase have been iden-
tified and removed (see Figure 2).
Slope half-life - the time needed for parasitaemia to be
reduced by half during the log-linear phase of parasite
clearance. This is a constant independent of the starting
value of parasitaemia since reduction in parasitaemia fol-
lows the first order process (after excluding lag phase
and tail). Half life can be calculated from the formula
T1/2 =l o g e (2)/K = 0.692/K, where K is the clearance rate constant.
Serial parasitaemia-time data obtained from several pub-
lished studies carried out between 2001 and 2010, at sites
located in Tak province in north-western Thailand, Chit-
tagong and Bandarban in Bangladesh, Savannakhet pro-
vince in Laos, western Cambodia and Mali were used in
the analysis. All studies investigated the use of artemisinin
combination therapies. The algorithm was also tested on
Figure 1 Typical linear, quadratic or cubic-shaped log(parasitaemia)-time profiles (polynomial fit shown in pink line) in falciparum
malaria. Black points represent the data, green points represent censored values and red points represent points removed in the cleaning
process.
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in Ho Chi Minh City, Vietnam between 1991-1996.
When there were no zero parasitaemias recorded, nor-
mal regression was used and all recorded measurements
were included in the analysis. When there were zero
parasitaemias recorded tobit regression [20] was used,
however only the first zero sustained (i.e. followed by
negative slides only) was included in the analysis. Briefly,
a tobit model is a censored regression model, where the
response variable Yi is related to a latent (and some-
times unobservable) variable Y∗
i by:
Yi =Y ∗
i if Y∗
i > YL,Y i =Y L if Y∗
i ≤ YL.
The latent variable is modelled in the standard way:
Y∗
i =X iβ + ε. The regression model is solved using maxi-
mum likelihood techniques, however the likelihood
function is now a truncated normal distribution in the
case when Y∗
i ≤ YL.
For each patient’s parasitaemia data, the following
polynomial models of time were fitted:
loge(Pi)=X iβ + εi
Where Pi is the parasite count per microlitre mea-
s u r e da tt i m et i and εi is the corresponding error term
associated with this measurement. b is a vector of
unknown parameter values and Xi is a vector of covari-
ate values as follows:
1. Linear: Xi = [1, ti], b =[ b 0,b 1]
2. Quadratic: Xi =[ 1 ,t i,t 2
i ], b =[ c 0,c 1,c 2]
3. Cubic: Xi =[ 1 ,t i,t 2
i ,t 3
i ], b =[ d 0,d 1,d 2,d 3]
For subjects with only four positive parasite measure-
ments, the cubic regression model could not be fitted so
a linear regression model starting from the second para-
site measurement was fitted if this second measurement
exceeded the first measurement (at time 0) by more than
25%. These “maximum regression” models often fitted
better than the quadratic models that typically do not fit
well for data with a steep increase in parasitaemia.
Linear, quadratic and cubic models fitted to the same
data were compared using Akaike Information Criterion
( A I C )[ 2 1 ]a n dt h em o d e lt h a tm i n i m i s e dt h eA I Cw a s
selected as best describing changes in log-parasitaemia
over time. For subjects with a “maximum regression”
model fitted, the sum of the squared residuals for the
observations common to all three models (RSSshared)w a s
used instead and the model that minimised the RSSshared
was selected. From the selected best fitting model the lag
phase was identified and the clearance rate constant was
estimated using the algorithm described below.
A sensitivity analysis was also performed to assess the
effect of parasite sampling times, the exclusion of lag-
phase from the estimation, and the use of tobit regres-
sion on estimates of the slope half-life. In order to do
this, slope half-life estimates were also calculated using
the following methods:
1. as described in this paper on a subset of patients
with measurements taken every six hours in the first
two days; with every second data-point excluded
from the estimation;
2. linear regression (tobit or normal regression as
appropriate), i.e. ignoring the lag phase;
3. normal regression wherea l lz e r o - c o u n t sw e r e
excluded from the estimation, but the lag-phase was
evaluated as described.
Each of the results from the above models (denoted
here by B) were compared with results from fitting
models using the methodology described in this paper
(denoted here by A). The relative difference in slope
half-life was calculated as:
(Slope half-lifeB − Slope half-lifeA)/Slope half-lifeA × 100%
Algorithm
Before model selection and fitting, the data are checked
for problem data points, possible outliers, and persistent
parasite tails in an automated fashion. The data cleaning
process is outlined briefly in Additional File 1. Having
determined that it is appropriate to fit a model to the
subject’s parasite count data, the model fitting and esti-
mation of the clearance rate constant (K) and duration
of lag phase (tlag ) is performed. The methodology is
summarized in the following steps:
Figure 2 The effect of lag phase and tail exclusion on the
calculation of the clearance rate constant.
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Step 1: Perform data cleaning, as described in Addi-
tional File 1. All further steps are performed on data
with outliers, tails, extreme values and trailing zeros
removed. For convenience of notation, if there is a
zero parasitaemia that directly follows the last posi-
tive parasitaemia, it is replaced with the detection
limit. This data point is subsequently counted as a
non-zero parasite count.
Step 2: Perform checks to see if the clearance rate
constant cannot be estimated:
(i) Number of non-zero parasite measurements
(including a zero replaced with the detection limit)
less than three
(ii) Initial parasitaemia too low: initial parasitaemia
< 1,000 parasites per microlitre
(iii) Final recorded parasitaemia too high: final para-
sitaemia ≥ 1,000 parasites per microlitre
(iv) A zero parasitaemia has been recorded, but the
last positive parasitaemia is too high and the zero
count is uninformative: last non-zero parasitaemia
≥ 1,000 parasites per microlitre
A zero parasitaemia is defined to be uninformative if
the normal linear regression fitted to all the data
points (excluding the zero count) gives a confidence
interval for the time when the parasitaemia is below
the level of detection which includes the time-point
when the zero parasitemia was recorded.
Step 3: Perform additional check to see if there are
not enough data to estimate a lag phase
(v) There are fewer than three measurements in the
first 24 hours or a time difference between measure-
ments in the first 24 hours is more than 14 hours;
Step 4: Perform model fitting.
If none of the exclusion criteria (i)-(iv) in Step 2 and (v)
in Step 3 are satisfied, fit polynomial models to the natural
log-parasitaemia versus time data as described in Figure 3.
If none of the exclusion criteria (i)-(iv) in Step 2 are
satisfied but exclusion criterion (v) in Step 3 is satisfied
fit tobit linear regression if a zero parasitaemia has been
recorded or linear regression otherwise.
If one or more of the exclusion criteria are satisfied in
Step 2, the clearance rate constant and duration of lag
phase cannot be estimated so proceed to Step 6.
Step 5: Estimate clearance rate constant (K) and dura-
tion of lag phase (tlag ) as described in Figure 4.
Step 6: END
Estimation of clearance rate constant and duration of lag
phase
The procedure to estimate the parasite clearance rate
constant depends on the shape of the parasite profile, i.
e. the shape of the best polynomial model fitted and the
amount of data available. For profiles with only three
parasite counts, infrequent parasite measurements in the
first 24 hours, profiles which are linear or exhibit con-
cave curvature, the minus slope of the linear regression
model or tobit linear model (where appropriate) is used
as an estimate of the clearance rate constant. Profiles
which exhibit convex curvature are examined further to
define the lag phase. If a lag phase is not identified in
the profile, then the minus slope of the linear regression
model or tobit linear model is used as an estimate of
the clearance rate constant.
For profiles with convex curvature the assessment is
performed on the best model predicted values with
respect to changes in pair-slopes - slopes calculated
between two neighbouring data points. Most pair-slopes
are negative since the parasitaemia is decreasing and the
smallest slope corresponds to the fastest parasite clear-
a n c e .F i r s t ,t h em i n i m u mp o s s i b l epair-slope is found
for the entire profile within the time interval of detect-
able parasite measurements. If the profile is linear then
all pair-slopes would be similar to this minimum slope,
but if there is pronounced curvature in the profile, then
there would be pair-slopes which are near to zero (cor-
responding to the flat part of the curve). If this flat part
of the curve occurs at the initial time-points then it is
called the lag phase and is excluded from the estimation
of the parasite clearance rate constant. However the
data-point which is the upper limit for the lag phase
period is included in calculations (i.e. if the duration of
lag phase is 12 hours then the data-point at 12 hours is
included in the final estimation of the clearance rate
constant).
Results
The algorithm was tested on a large data set, consisting
of 4,236 individual patient parasite-time profiles from
clinical studies of ACT: artesunate monotherapy, artesu-
nate and mefloquine, artemether and lumefantrine, arte-
sunate and amodiaquine. The median number (range) of
positive parasite slide readings was seven (three-33) per
patient. The detection limit was 16 (in 81% of patients),
25 (in 4% of patients) or 40 (in 15% of patients) para-
sites per microlitre. Within this large data-set, 4,008
profiles had their parasite clearance rates calculated, of
which 294 profiles were best fitted with a quadratic
model and a non-zero lag phase, 883 profiles were best
fitted with a cubic model (and non-zero lag phase), and
2,821 were best fitted with a linear model (either
directly (1,146 profiles), or by a quadratic model with
zero lag phase (704 profiles) or by a cubic model with
zero lag phase (971 profiles)). The breakdown of fitted
models is provided in Table 1. We note that of the
2,831 fitted with a linear model, 55 of these had only 3
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linear model).
Of the 228 profiles that did not pass the requirements
for clearance rate estimation, 112 were not fitted
because of a lack of data (< 3 positive parasite readings),
27 because the initial parasitaemia was too low, and 89
because the parasitaemia was not cleared (last recorded
parasitaemia was above 1,000 parasites per microlitre).
Among 4,008 patients for whom estimation could be
performed, tails were identified in 1,070 profiles (27%).
In the automated cleaning process, a total of 31 outliers
were identified. These points were not included in any
subsequent clearance rate calculations. A lag phase was
estimated in 30% (1,187/4,008) of profiles; the median
(IQR; range) duration of lag phase was six (6-9; 1-60)
hours.
Summary of model outputs and examples of fit
For the 4,008 profiles fitted, the median (IQR; range)
parasite clearance rate constant was 0.22 (0.16-0.30;
0.02-1.18) per hour. The corresponding slope half-life
had a median (IQR; range) of 3.11 (2.33-4.24; 0.59-
34.28) hours. It should be noted that the data used in
this paper has come from multiple study sites, across a
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Figure 3 Flow chart showing the models tested during the process of finding the best model representing parasite clearance over
time for an individual patient.
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Page 6 of 13range of patient demographics and, as such, should not
be used as a reference point for comparison to other
parasite clearance data.
Figure 5 shows examples of individual log-parasitae-
mia - time profiles, with linear and polynomial fits to
the data. The clearance rate constants calculated by a
linear fit applied to all data points were consistently dif-
ferent to the clearance rate constants calculated by
accounting for the lag phase (detailed comparisons
between the slope half-life calculated using the lag
regression technique to those calculated by fitting a lin-
ear model to the data are presented below).
Goodness of fit
Agreement between predicted and measured log-parasi-
taemia was better for the final linear models derived
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Figure 4 Diagrammatic representation of the process of estimating the clearance rate constant (K) and the duration of lag phase (tlag )
from individual patient parasite counts measured over time.
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sion models fitted to all data points: the residuals had
smaller variation over the data used to calculate the
clearance rate constants: their mean (standard deviation)
for the time points included in estimation of the clear-
ance rate constant was 0.00 (0.42) for the polynomial
models and 0.09 (0.80) for the corresponding linear
models. Figure 6 shows a plot of the standard deviation
of the residuals for all profiles fitted versus the number
of data points used to calculate the slopes of the linear
part of the parasite clearance profiles. Overall, as
expected, there is a decrease in the variability of stan-
dard deviation of the residuals as the number of parasite
counts in the linear part of the parasite clearance profile
increases, although the median value of the standard
deviation of the residuals remains the same as sample
size increases.
Comparison between lag regression and linear regression
Among profiles with a lag phase (30%; n = 1187) identi-
fied, the linear regression models tended to overestimate
the slope half-life; the median (IQR; range) of the rela-
tive difference in slope half-life was -18% (-28% to -11%;
-397% to 35%). The differences decreased with the
increased duration of the lag phase (Figure 7). For the
subset of data where a lag phase of approximately six
Table 1 Breakdown of models fitted.
Number of models fitted (% of total)
Linear fit 1146 (28.6%)
Max reg fit 10 (0.3%)
Quadratic fit (total) 998 (24.9%)
tlag = 0 704 (17.6%)
tlag > 0 294 (7.3%)
Cubic fit (total) 1854 (46.2%)
tlag = 0 971 (24.2%)
tlag > 0 883 (22.0%)
Figure 5 Linear and polynomial fits to the quadratic or cubic -shaped log(parasitaemia)-time profiles shown in Figure 3. Black points
represent the data, green points represent censored values and grey points represent points identified as being part of the lag phase. Pink line
shows cubic fit to the data, red line shows linear fit the data and blue line shows the linear fit to the identified ‘linear part’ of the profile.
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relative difference in the slope half-life was -15% (-22 to
-10%; -102% to 35%) as compared to -76% (-114% to
-52%; -397% to 6%) for a lag phase of approximately 18
hours or more.
Frequency of sampling
Among all patients for whom estimation was performed,
1,715 had parasite counts taken at regular six-hour
intervals in the first 48 hours. In order to assess whether
less frequent sampling would be adequate for slope esti-
mations, the clearance rate constant and slope half-life
were estimated after removal of every second data point
(i.e. including only parasite counts taken every 12 hours)
and compared with the estimates based on all data
(Figure 8). The agreement between estimates was better
for profiles without a lag phase and with a minimum of
four counts in the linear segment of the profile (after
excluding lag phase and tail) (Figures 9 and 10). Slope
half-life tended to be overestimated when 12 hourly
measurements were used. The median (IQR; range) rela-
tive difference in slope half-life was -4.8% (-17.3% to
1.2%; -190.9% to 50.9%). The difference in slope half-life
was mostly due to (a) unidentified lag phase when 12
hourly measurements were used and (b) delayed record
of zero parasite count. In both situations a line with a
f l a t t e rs l o p ew a sf i t t e dc o m p a r e dt ot h ef i tw i t hs i x
hourly data.
Figure 6 The standard deviation of the residuals versus the
sample size of the linear part of the parasite clearance profile.
Figure 7 The relative difference in slope half-life rate
comparing the final slope half-life to that calculated by fitting
a linear model to all the data. (Note that only those profiles for
which tlag > 0 were used here, for comparison purposes). Relative
difference in slope half-life is calculated as the slope half-life from
lag regression minus the slope half-life from linear regression,
divided by the slope half-life from lag regression.
Figure 8 The comparison between slope half-life estimated
from parasite measurements taken every six and 12 hours in
the first two days.
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measurements, the percentage of profiles with an abso-
lute relative difference in slope half-life above 10% was
19% for sample size of four or more counts (of the lin-
ear part of the 12 hour data), decreasing to 7% for a
sample size of at least six and 0.6% for nine or more
data points. The corresponding figures for an absolute
difference of 20% or more were 7%, 3% and 0.3%.
If a lag phase was identified using six-hourly measure-
ments, the relative differences in slope half-life was
greater; 21% of profiles with a sample size of four or
more in the linear segment of the 12-hour data were
different by more than 30%. The estimated duration of
lag phase did not change in 1,204 of the 1,696 profiles
(71%). However, of these 1,204 profiles 1,167 (97%) were
profiles with no lag phase identified by both models
(Table 2).
Of 517 profiles with a lag phase detected by the six-
hourly measurements, the majority (79%) had the esti-
mate of the duration of lag phase shortened when 12-
hourly measurements were used, resulting in a systema-
tic overestimation of the slope half-life. The median
(IQR; range) relative difference in slope half-life for
those profiles that had both a lag phase detected with
the six-hourly measurements and this lag phase shor-
tened under the 12-hourly measurements was -25.1%
(-40.2% to -16.0%; -190.9% to 28.8%). Overall this analy-
sis indicates that parasite clearance profiles with a lag
phase are poorly characterised if the first parasite count
after baseline is taken at 12 hours.
Use of tobit regression
The algorithm was tested on the 2,401 profiles which
required tobit regression. The median relative difference
in slope half-life between tobit regression and normal
regression was -0.01% with a range of (-134% to 71%).
Overall 14.4% of slopes had an absolute difference of
more than 10% and only 4.4% of profiles had a differ-
ence of more than 30% (Table 3). Even though there is
little overall difference between estimates when normal
regression was used instead of the tobit regression, in
Figure 9 Relative difference in slope half-life estimated from
six-hourly and 12-hourly measurements, by sample size. Left
panel shows results for profiles with no lag phase identified based
on six-hourly measurements; right panel shows results for profiles
with lag phase. Sample size is equal to number of measurements at
12-hourly intervals in linear part of profile (after excluding lag phase
and tails). Relative difference in slope half-life is calculated as the
slope half-life from six-hourly measurements minus the slope half-
life from 12-hourly measurements, divided by the slope half-life
from six-hourly measurements.
Figure 10 Box-plots of relative difference in slope half-life
estimated from six-hourly and 12-hourly measurements,
stratified by lag phase (tlag). Relative difference in slope half-life is
calculated as the slope half-life from six-hourly measurements minus
the slope half-life from 12-hourly measurements, divided by the
slope half-life from six-hourly measurements.
Table 2 Summary of changes in lag phase when 12-
hourly parasite counts were used instead of six-hourly
counts.
Duration of lag phase (hours)
a
Change in tlag 0 hours
b 6 hours 12 hours 18 hours
c
Decreased 0 (0%) 354 (84%) 42 (53%) 12 (80%)
Remains unchanged 1167 (99%) 0 (0%) 37 (47%) 0 (0%)
Increased 12 (1%) 69 (16%) 0 (0%) 3 (20%)
Values presented in brackets is the percentage of the column sum.
anumber of patients (%) given
bno lag phase was identified
cduration of lag phase of 18 hours or longer
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difference could be substantial.
Different anti-malarial drug treatments
The algorithm was tested on data from a study of 382
patients investigating the effect of quinine on parasite
clearance. The median number (range) of positive para-
site counts from slide readings was seven (three-30) per
patient. Overall, 285 profiles were suitable for estimation
of parasite clearance rates, of which 36 profiles were
best fit with a quadratic model and a nonzero lag phase,
70 profiles were best fit with a cubic model and nonzero
lag phase, and 179 were best fit with a linear model
(either directly, or by a higher order model with zero
lag phase). Of the 97 profiles that did not pass the
requirements for clearance rate estimation, four were
not fitted because of lack of data (< 3 positive parasite
counts), 15 because the initial parasitaemia was too low,
and 78 because the parasitaemia was not cleared (last
recorded parasitaemia was above 1,000 parasites per
microlitre). Among the patients for whom estimation
could be performed, tails were identified in 45 profiles
(16%) and 106 had a non-zero lag phase (37%).
Overall, the median (IQR; range) slope half-life for
patients treated with quinine was 5.15 (3.83-6.68; 0.86-
105.5) hours and, as expected, was longer than for ACT.
Median (IQR; range) slope half-life for ACT was 3.11
(2.33-4.24; 0.59-34.28) hours. Patients treated with qui-
n i n ew e r em o r el i k e l yt oh a v eal a gp h a s e( 3 7 %versus
30% in the ACT group) and the duration of lag phase
was significantly longer: median (IQR; range) of 10.0
(6.31-18.13; 0.5-81.97) hours as compared to six (6-9; 1-
60) hours in ACT group.
For the quinine data-set, as with the data-set from
patients treated with ACT, the agreement between the
predicted and measured log-parasitaemia was better for
the final linear models derived from the polynomial
models than for the linear regression models fitted to all
data points: the residuals had smaller variation over the
d a t au s e dt oc a l c u l a t et h ec l e a r a n c er a t ec o n s t a n t :t h e
mean (standard deviation) for the time points included
in estimation of the clearance rate constant was 0.00
(0.39) for the polynomial models and 0.17 (1.08) for the
corresponding linear models.
Conclusions
Prolonged parasite clearance is the only way artemisinin
resistance can be identified currently. In this paper a
new standardized approach to the estimation of the
malaria parasite clearance rate has been presented. The
algorithm takes into consideration the potentially con-
founding effects of the lag phase and removes these
initial data before calculating the rate constant of the
log-linear phase of parasite clearance. An outline of the
algorithm is presented and its use has been evaluated
with a large series of serial parasite counts from treat-
ment studies in patients with acute falciparum malaria.
Current evidence suggests that the main effect of arte-
misinin resistance is on the slope of the log-linear
decline and for this reason this paper has focussed on
characterizing this variable. The slope measure which
may be most readily interpreted by malariologists is the
half-life (which is inversely proportional to the first
order rate constant).
The clinical phenotype of delayed parasite clearance is
likely to remain the main proxy of artemisinin resistance
until molecular markers are identified or in vitro meth-
ods adapted which provide better characterization. Para-
site clearance rates are affected by drug blood
concentration profiles as well as their pharmaco-
dynamic properties. Immunity also increases parasite
clearance rates. Other factorss u c ha ss p l e n i cf u n c t i o n ,
age, anaemia and co-infections may also affect parasite
clearance and require further investigations.
Whilst artemisinin resistance in P. falciparum is con-
fined to a relatively small geographic area in SE Asia, it
is important to establish in other areas baseline parasite
clearance data for the different ACT provided through
the public sector, so trends can be followed prospec-
tively across malaria endemic countries. The accurate
assessments of parasite clearance in this “early warning
system” require frequent blood sampling and accurate
counting and the additional workload and the necessary
quality assurance of such monitoring measures will
undoubtedly raise serious operational challenges.
How frequent do parasite counts need to be to pro-
vide reliable calculation of estimates is still unclear.
Measuring parasitaemia every 12 hours after starting
treatment until counts are below the level of detection,
allows the calculation of parasite clearance rates but sys-
tematically overestimates the slope half-life compared to
measurement every six hours. The difference observed is
greater when there is a lag phase, and is more evident
with certain anti-malarials, e.g. quinine compared to
artemisinin derivatives.
Table 3 Agreement between tobit regression and linear
regression estimates of slope half-life.
Relative Difference in Slope half-life
a
Sample size
b < 10% < 30% < 50%
3<N≤ 5 620 (90%) (26, 44) 669 (97%) (9, 12) 683 (99%) (5, 2)
5<N≤ 10 1104 (81%) (19, 242) 1281 (94%) (2, 82) 1352 (99%) (1, 12)
10 < N ≤ 15 331 (96%) (7, 8) 346 (100%) (0, 0) 346 (100%) (0, 0)
The two numbers in brackets represent the percentage within the threshold
and the number of cases below and above the margin respectively.
a Number of patients (%) within margin and (number of patients below
margin, number of patients above margin) are given
b Number of observations in the linear part of the parasite clearance profile
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pling design for parasite clearance characterisation.
However, considering the field challenges of performing
systematic measures of parasitaemia more frequently
than 12-hourly, this sampling interval could be consid-
ered as the minimum.
The WorldWide Anti-malarial Resistance Network
(WWARN) has developed the Parasite Clearance Esti-
mator or PCE (see http://www.wwarn.org/research/para-
site-clearance-estimator for details), which uses the
methodology described above to estimate parasite clear-
ance measures. WWARN aims at providing a platform
of partnership, which facilitates gathering the necessary
data across endemic countries, needed to answer to the
different methodological questions raised above.
Identifying the clearance rate constant and lag phase
w i t ht h ei m p r o v e dm e t h o do u t l i n e dh e r ew i l lp r o v i d e
necessary standardized information in order for warning
s i g n so fr e s i s t a n c et ob ed e t e c t e d ,s ot h a ta p p r o p r i a t e
actions to contain resistance can be initiated [6].
Additional material
Additional file 1: Data cleaning process for the parasite clearance
estimator. The cleaning process implemented in the algorithm is
described, including removal of recurrence parasitaemia, trailing zeros,
tails, replacement with the detection limit, extreme values and outliers.
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